{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971811",
  "id": "02971811",
  "pages": 10,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0953",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1vpxzzkc238.pdf",
  "summary": "### **Capital Raising Announcement Summary**:  \n**Structure**:  \n- **Placement**: 96,804,354 shares at **A$0.23** per share (total ~**A$22.27m**), issued **29/7/2025**.  \n  - Uses **15% placement capacity** (57,937,087 shares) + **10% capacity** (38,867,267 shares).  \n- **SPP**: Up to 10,869,566 shares (potential **A$2.5m**, max **A$10m** if oversubscribed).  \n  - Price: Lower of **A$0.23** or **5% discount** to 5-day VWAP post-offer.  \n  - **Timetable**:  \n    - Record date: **22/7/2025**  \n    - Offer close: **22/8/2025**  \n    - Issue date: **29/8/2025**.  \n\n**Conditions**:  \n- **SPP** and **A$5.23m** of Placement subject to **shareholder approval** (AGM: **27/8/2025**).  \n\n**Use of Proceeds**:  \n- Clinical trials (Phase 2b/3), drug manufacturing, working capital (~**A$27.5m** total raised).  \n\n**Broker Fees**: **5.5%** (Bell Potter Securities).  \n\n**Key Limitation**:  \n- SPP capped at **A$100k** per shareholder.  \n\n*(Omitted: Legal/registry fees, non-eligible jurisdictions, escrow details.)*",
  "usage": {
    "prompt_tokens": 3852,
    "completion_tokens": 342,
    "total_tokens": 4194,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:57:15.801998"
}